Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual ...

Please provide your email address to receive an email when new articles are posted on . Use of a precision navigator led to significant increase in genomic profiling among men with prostate cancer.

Here is how robotic surgeries are paving way for new gen cancer treatment in the country - Read on to know all about it.

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...

Current prostate specific antigen (PSA) testing "may not effectively target testing to those most likely to benefit, raising concerns about overtesting" warn researchers from the University of Oxford ...